Xeris Biopharma Holdings, Inc. (XERS) › Cash & EquivalentsXeris Biopharma Holdings, Inc. (XERS) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $19.52M2020: $37.60M2021: $67.27M2022: $121.97M2023: $67.45M2024: $71.62M2025: $111.04M$111.04M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$111.04M+55.0%2024$71.62M+6.2%2023$67.45M-44.7%2022$121.97M+81.3%2021$67.27M+78.9%2020$37.60M+92.6%2019$19.52M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share